Login to Your Account



Clinic Roundup


Monday, April 25, 2011
Idera Pharmaceuticals Inc., of Cambridge, Mass., said it will delay its planned Phase II study of Toll-like receptor 9 agonist IMO-2125 based on preliminary data from a 26-week nonclinical toxicology study in rodents showing instances of atypical lymphocytic proliferation.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription